KRISTIN WINTERNHEIMER: Open Payments
NPI 1629732896 · CARMEL, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,036 in 62 payments from 13 companies in 2025. Trend: 2023 $159 · 2024 $799 · 2025 $1,036
Food & beverage: $1,036
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $204 |
| Novo Nordisk Inc | 11 | $186 |
| Lilly USA, LLC | 16 | $179 |
| AstraZeneca Pharmaceuticals LP | 4 | $153 |
| Neurocrine BioSciences, Inc. | 3 | $77 |
| PFIZER INC. | 5 | $75 |
| Amgen Inc. | 3 | $47 |
| Astellas Pharma US Inc | 2 | $35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $24 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
Products named: MOUNJARO, BREZTRI, Ozempic, INGREZZA, UBRELVY, Wegovy, QULIPTA, JARDIANCE.
Industry payments across IN — which companies pay providers there.
